Treatment of glossodynia with olanzapine

Journal of the American Academy of Dermatology

Volumn 51, Issue 3, 2004, Pages 463-465

  Gick, Carrie L ^a   Mirowski, Ginat W ^a   Kennedy, John S ^a   Bymaster, Frank P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CEVIMELINE; CLOTRIMAZOLE; LORAZEPAM; OLANZAPINE; PAROXETINE; TERAZOSIN; TRIAMCINOLONE;

AGED; ANALGESIA; ANAMNESIS; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DYSPHORIA; FOLLOW UP; GLOSSODYNIA; HUMAN; MALE; MENTAL DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 4444348509     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.02.016     Document Type: Article

References (21)

1. Dutree-Meulenberg R.P.G.M., Kozel M.M.A., van Joost T. Burning mouth syndrome: A possible etiologic role for local contact hypersensitivity. J Am Acad Dermatol. 26:1992;935-940
2. Huang W., Rothe M.J., Grant-Kels J.M. The burning mouth syndrome. J Am Acad Dermatol. 34:1996;91-98
3. Helton J., Storrs F. The burning mouth syndrome: lack of a role for contact urticaria and contact dermatitis. J Am Acad Dermatol. 31:1994;201-205
4. Drage L.A., Rogers R.S. III. Clinical assessment and outcome in 70 patients with complaints of burning or sore mouth symptoms. Mayo Clin Proc. 74:1999;223-228
5. Ship J.A., Grushka M., Lipton J.A., Mott A.E., Sessle B.J., Dionne R.A. Burning mouth syndrome: an update. JADA. 126:1995;842-853
6. Tanaka M., Kitago H., Ogawa S., Tokunaga E., Ikeda M., Tomita H. Incidence and treatment of dysgeusia in patients with glossodynia. Acta Otolaryngol. 546:2002;142-145
7. Gorsky M., Silverman S. Jr., Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome: an open study of 130 patients. Oral Surg Oral Med Oral Pathol. 72:1991;192-195
8. Drage L.A., Rogers R.S. III. Glossodynia. Lebwohl M.G., Heymann W.R., Berth-Jones J., Coulson I. Treatment of skin disease: comprehensive therapeutic strategies. 2002;237-239 Mosby, London
9. Regezi J.A., Sciubba J.J., Jordon R.C.K. Oral pathology: clinical pathologic correlations. (4th ed) :2003;123-125 Saunders, St. Louis, MO
10. Bogetto F., Maina G., Ferro G., Carbone M., Gandolfo S. Psychiatric comorbidity in patients with burning mouth syndrome. Psychosom Med. 60:1998;378-385
11. Grushka M., Epstein J., Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Path Oral Radiol Endod. 86:1998;557-561
12. Godfrey R.G. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Int Med. 156:1996;1047-1052
13. Sindrup S.H., Jensen T.S. Pharmacologic treatment of pain in polyneuropathy. Neurology. 55:2000;915-920
14. Kiser R.S., Cohen H.M., Freedenfeld R.N., Jewell C., Fuchs P.N. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage. 22:2001;704-708
15. Khojainova N., Santiago-Palma J., Kornick C., Breitbart W., Gonzales G.R. Olanzapine in the management of cancer pain. J Pain Symptom Manage. 23:2002;346-350
16. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol. 14:1996;87-96
17. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., Truex L.L., et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1and alpha1-adrenergic receptors in vitro. Schizophr Res. 37:1999;107-122
18. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck K., DeLapp N.W., et al. Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine. Eur J Pharmacol. 430:2001;341-349
19. Schreiber S., Getslev V., Backer M.M., Weizman R., Pick C.G. The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency. Pharmacol Biochem Behav. 64:1999;75-80
20. Bymaster F.P., Falcone J.F. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Eur J Pharmacol. 390:2000;245-248
21. Kennedy J.S., Bymaster F.P., Schuh L., Calligaro D.O., Nomikos G., Felder C.C., et al. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry. 16:(suppl):2001;S33-S61